timothy sykes logo

Stock News

Microbot Medical’s Growth: Opportunity or Hype?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 11/28/2025, 9:19 am ET | 5 min
Microbot Medical’s Growth: Opportunity or Hype? Thumbnail

In this article

  • MBOT+7.42%
    MBOT - NASDAQMicrobot Medical Inc.
    $2.46+0.17 (+7.42%)
    Volume:  1.52M
    Float:  63.97M
    $2.40Day Low/High$2.69

Microbot Medical Inc.’s stocks have been trading up by 9.83 percent driven by promising product development and strategic partnerships.

  • In a significant announcement, Emory University Hospital is not only implementing the Liberty system but is also partnering with Microbot to establish a specialized Endovascular Robotics Program, strengthening its position in the medical field.

  • Recent limited market release of the Liberty system sees Microbot Medical bringing forward their FDA-approved robotic technology, focusing on gaining practical insights from regions with high procedure volumes.

Candlestick Chart

Live Update At 09:18:39 EST: On Friday, November 28, 2025 Microbot Medical Inc. stock [NASDAQ: MBOT] is trending up by 9.83%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Snapshot

In the world of trading, resilience and adaptation are key components to success. Each day in the market presents new challenges and opportunities, and it’s crucial to continue learning and refining your skills. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” By adopting this mindset, traders can navigate the volatile nature of markets and become more adept at making informed decisions, transforming setbacks into stepping stones for future growth.

Microbot Medical has been making waves with the latest advancements, but let’s dive into the numbers. Despite some remarkable innovation in healthcare robotics, the company’s financials depict a mixed picture.

Financial Strength and Key Ratios

With a current ratio of 27.5, Microbot Medical stands strong in its ability to cover short-term liabilities. The quick ratio at 27.3 also signals ample liquid assets. Interestingly, their total debt to equity is astonishingly low at 0.01, showing a judicious approach to debt management.

Income and Revenue Insights

In terms of income, the reports show losses that might raise eyebrows. For the third quarter ending Sept 30, 2025, the company faced an operating loss with EBITDA recorded at negative $3.85M. Despite these figures, revenue potential is palpable, especially with burgeoning interest in their robotic systems.

More Breaking News

Cash Flow and Investments

The cash flow statements indicate substantial investments in long-term projects such as Liberty, with capital expenditures tallied at $13K. The net cash position, increasing to $3,595,000, echoes prudent cash management, hinting at strategic future deployments.

The Story Behind the Surge

Emory University’s Strategic Leap

When Emory University Hospital embraced Microbot’s Liberty System, it wasn’t just a procurement; it was a pioneering move. Traditionally, hospitals take cautious steps into robotics. Here, Emory not only accepted but also engaged with Microbot directly, establishing a program that stretches the horizon of interventional radiology.

Market Dynamics and Future Outlook

The broader implications for MBOT stocks are substantial. With global healthcare innovation at the forefront, investors see the Liberty adoption as more than a mere deal—it’s an entry point to a world where robotics and medicine converge. Market bullishness is evident as investors anticipate stronger performance backed by this potential game-changer.

Impacts on Valuation

Despite current financial losses, the potential of the Liberty System suggests a paradigm shift. Traders look beyond present numbers, focusing on the potential rise in stock prices as the company grows and garners more institutional trust. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.”

In conclusion, Microbot Medical Inc. may not yet show stellar financials, but the strategic adoption by Emory University paints a forward-looking image. While the stock enjoys momentary applause, longer-term prospects hinge on how effectively Microbot builds on this momentum. The question remains—Is this a golden opportunity or just the beginning of a hype cycle? The answer lies in what comes next.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”